Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.42 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21715297 | 1.00 | MAPT (0.53) | MAPTKLK7KLK5SYKFOLH1 | |
| SCHEMBL16762042 | 0.90 | CACNA1B (0.41) | MAPTITGB3ITGA2B | |
| SCHEMBL20211129 | 0.90 | CACNA1B (0.41) | MAPTITGB3ITGA2B | |
| SCHEMBL15238498 | 0.87 | L3MBTL1 (0.42) | MAPTSYKFOLH1ATM | |
| SCHEMBL28820385 | 0.87 | L3MBTL1 (0.42) | MAPTSYKFOLH1ATM | |
| SCHEMBL21715246 | 0.86 | MAPT (0.56) | MAPTKLK7KLK5FOLH1ITGB3 | |
| SCHEMBL29627360 | 0.86 | MAPT (0.56) | MAPTKLK7KLK5FOLH1ITGB3 | |
| SCHEMBL29627370 | 0.85 | MAPT (0.55) | MAPTKLK7KLK5SYKFOLH1 | |
| SCHEMBL17397484 | 0.83 | PPARA (0.40) | SYKATM | |
| SCHEMBL17009235 | 0.83 | CTSK (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | 7 HILLS PHARMA INC. (US) | 2025-01-21 | — | — | US | claimed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | MAPT 3555/4885KLK7 403/4885KLK5 1464/4885 |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | MAPT 1861/4885KLK7 1009/4885KLK5 2006/4885 |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | CD47, CD274, ITGB1 | MAPT 2860/4885KLK7 2170/4885KLK5 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.